Recent developments include clinical enrollment milestones in the Phase 3 trial of PF614, extension of patent protection on MPAR technology, improved financial results, and strategic partnerships.

• Ensysce Biosciences reached 50% enrollment milestone in the pivotal Phase 3 trial of PF614 [N5].
• The company reported an extension of patent protection on its MPAR technology aimed at preventing opioid abuse [N3].
• Ensysce announced improved financial results in recent reporting [N4].
• The company announced a partnership with a specialty drug manufacturer to support development and manufacturing [N8].
• Dosing of first subjects in the PF614-MPAR clinical trial was reported [N8].

Ensysce’s proprietary TAAP and MPAR® platforms represent innovative approaches to addressing opioid abuse and overdose, with clinical data supporting safety, pharmacokinetics, and abuse resistance. The FDA Breakthrough Therapy designation for PF614-MPAR highlights regulatory recognition of the technology’s potential. The ongoing pivotal Phase 3 trial for PF614 and clinical studies for PF614-MPAR mark significant development milestones. The company’s focus on unmet needs in opioid safety and abuse deterrence, combined with patent protection and partnerships for manufacturing, underpin its strategic positioning in a large market with substantial societal impact [N5][N3][S1].

Ensysce faces significant risks including its lack of approved products and revenues, ongoing operating losses, and liquidity constraints with substantial doubt about its ability to continue as a going concern. Clinical development is inherently uncertain, and failure to achieve regulatory approvals or demonstrate clinical efficacy and safety could impede commercialization. The company depends on third-party manufacturers and suppliers, which may pose risks to supply continuity and cost control. Competition from other pharmaceutical companies with abuse-deterrent or non-opioid pain products may limit market opportunities. Additionally, the company’s small size and limited operational history increase execution risks [S14][S10][S3].

Ensysce’s moat is based on its proprietary molecular-level abuse-deterrent technologies, TAAP and MPAR®, which differ from existing abuse-deterrent formulations by resisting both oral and non-oral abuse through enzyme-mediated activation and overdose protection mechanisms. The MPAR® technology’s unique overdose protection via trypsin inhibition is not known to have direct competitors, providing a potential competitive advantage. The company holds patents and intellectual property rights protecting these technologies and has received FDA Breakthrough Therapy designation for PF614-MPAR, which may facilitate regulatory interactions. However, the company remains in clinical development with no commercial products, and its competitive position depends on successful clinical and regulatory progress.

• Clinical and Regulatory Risk: The company’s product candidates are in clinical development and have not received regulatory approval. Clinical trials may not demonstrate safety or efficacy, and regulatory authorities may not approve the products.
• Liquidity and Going Concern Risk: Ensysce has reported substantial doubt about its ability to continue as a going concern due to ongoing losses and limited cash resources, requiring additional financing to fund operations.
• Manufacturing and Supply Risk: The company relies on third-party contract manufacturers for production of clinical and potential commercial supplies, which may face disruptions or regulatory challenges.
• Competition Risk: Other companies are developing abuse-deterrent opioid products and non-opioid pain treatments, which may compete with Ensysce’s product candidates.
• Intellectual Property Risk: The company’s commercial success depends on obtaining and maintaining patent protection and trade secrets. Infringement or inability to protect IP could harm the business.

• Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company focused on developing innovative solutions for severe pain relief while reducing opioid misuse, abuse, and overdose [S1].
• The company develops product candidates designed to improve the safety of prescription drugs, primarily opioid pain products and opioid use disorder products [S1].
• Ensysce's proprietary platforms include the Trypsin Activated Abuse Protection (TAAP) platform and the Multi-Pill Abuse Resistant (MPAR®) platform [S1].
• TAAP technology is a molecular delivery system designed to release active drugs only when exposed to specific physiological conditions, such as the digestive enzyme trypsin, aiming to deter abuse by oral and non-oral routes [S1].
• PF614 is the lead TAAP oxycodone prodrug candidate, designed to resist oral and non-oral abuse modes and has undergone multiple Phase 1 clinical trials demonstrating safety, pharmacokinetics, and bioequivalence to OxyContin [S1].
• PF614-MPAR is a combination product of PF614 and nafamostat (a trypsin inhibitor) designed to provide overdose protection by limiting active opioid release when taken in excess [S1].
• PF614-MPAR received FDA Breakthrough Therapy designation in January 2024 [S1].
• The company initiated a pivotal Phase 3 trial for PF614 in post-operative acute pain in July 2025 with enrollment starting December 2025 [S1].
• Ensysce relies on contract manufacturing organizations (CMOs) for clinical and potential commercial production of its product candidates, including controlled substances requiring DEA registration [S3].
• The company has no products approved for commercial sale and has not generated revenue from product sales; it has incurred significant losses since inception and expects to continue incurring losses [S10].
• As of June 30, 2026, Ensysce had cash and cash equivalents of approximately $677,000 and current assets of about $2.85 million, with current liabilities of approximately $4.07 million, resulting in a current ratio of 0.7 and a cash ratio of 0.17 [S2].
• The company has disclosed substantial doubt about its ability to continue as a going concern due to lack of revenue and dependence on additional financing [S14].
• Ensysce has eight full-time employees and two part-time employees, with five holding Ph.D. degrees [S15].
• Recent news highlights include reaching 50% enrollment milestone in the pivotal Phase 3 trial of PF614, extension of patent on MPAR technology, and reports of improved financial results [N5][N3][N4].
• The company announced a partnership with a specialty drug manufacturer and dosing of first subjects in the PF614-MPAR trial [N8].
• Ensysce's technology platforms differ from current abuse-deterrent formulations by focusing on molecular-level abuse resistance unaffected by physical manipulation [S6].
• The MPAR technology is unique in the market for providing overdose protection by inhibiting prodrug activation at higher-than-prescribed doses [S4].